



RESEARCH ARTICLE



Received on: 14-01-2014

Accepted on: 20-03-2014

Published on: 15-04-2014

Nida Dincel*

Ankara Children Health and Research
Hematology Oncology Education
Research Hospital, Ankara, Turkey
Email: nida_dincel@yahoo.com



Conflict of Interest: None Declared !

QR Code for Mobile users

Fc Gamma Receptor Polymorphism: A Risk Factor for Urinary Tract Infections

Rahmi Özdemir¹, Ebru Yılmaz², Nida Dinçel³, Betül Sözeri¹, Kadriye Özdemir⁴, Afig Berdeli⁵, Sevgi Mir⁴

¹Ege University Medical Faculty Department of Pediatrics

²Dr. Behcet Uz Children Health and Research and Children Surgery Education Research Hospital, Izmir, Turkey

³Ankara Children Health and Research Hematology Oncology Education Research Hospital, Ankara, Turkey

⁴Ege University Medical Faculty Pediatric Nephrology

⁵Ege University Medical Faculty Molecular Genetic

Abstract

Microorganisms adhere to uroepithelium and trigger adaptive immune response with synthesis of chemokine's and cytokines. Chemokine and chemokine receptors lead to recruitment of inflammatory cells results in inflammatory response: healing or scarring. FcR initiates effector functions: degranulation, cytokine, superoxide production, and arrangement of antibody synthesis, antibody dependent cellular cytotoxicity, and phagocytosis. Aim was to determine FcγR polymorphism role in urinary tract infection (UTI).

131 UTI and 151 healthy subjects without any urinary tract abnormality were participated. Polymorphisms were determined by amplification refractory mutation system PCR.

FcγRIIa R/R genotype and FcγRIIa R allele are found significantly higher in study group than control. FcγRIIIa genotype distribution and allele frequency is not significantly different between UTI and control group. FcγRIIIb-NA2/NA2 genotype and NA2 allele are found statistically higher when compared to control FcγRIIa-131-R allele is found to be related; lower UTI (p=0.015), gram negative bacterial infection risk (p=0.012) FcγRIIIb-NA2 allele is found to be related; upper UTI (p=0.001) gram negative bacterial infection (p=0.001), renal scar development risk (p=0.001). FcγRIIa-R131R and FcγRIIIb-NA2/NA2 gene polymorphisms may increase risk and susceptibility to UTI in children.

Keywords: FcγR gene polymorphisms, UTI, children

Cite this article as:

Rahmi Özdemir, Ebru Yılmaz, Nida Dinçel, Betül Sözeri, Kadriye Özdemir, Afig Berdeli, Sevgi Mir. Fc Gamma Receptor Polymorphism: A Risk Factor for Urinary Tract Infections. Asian Journal of Biomedical and Pharmaceutical Sciences; 04 (30); 2014; 19-25.

DOI: 10.15272/ajbps.v4i29.441

INTRODUCTION

Urinary tract infection (UTI) is one of the most common infections in childhood. The pathogenesis of UTIs is dependent primarily on two factors, host defense and pathogen related virulence (1).

Bacteria adhere to the uroepithelium and trigger an adaptive immune response with the synthesis of chemokine's and cytokines. Chemokine and chemokine receptors lead to the recruitment of inflammatory cells, resulting in an inflammatory response, followed by healing or scarring (2).

IgG is the predominant subclass of antibodies produced by immune cells in response to bacterial polysaccharide antigens. Fc receptor region (FcR) of immune globulins plays a crucial role in phagocytosis. FcR initiates effector functions, such as degranulation, cytokine production, and arrangement of antibody synthesis, antibody dependent cellular cytotoxicity, superoxide production, and phagocytosis. FcγR are divided in three classes: FcγRI (CD 64), FcγRII (CD 32), and FcγRIII (CD16) (3-7). These receptors differ in cell distribution and affinity for IgG subclasses and display heterogeneity between individuals according to genetic structure and ethnicity. The polymorphic nature, also known as diverse nature, of the FcγR, is a risk factor in certain infectious and autoimmune diseases (8).

FcγRIIIa is the only FcR class that interacts with the human IgG2 molecule located on chr.1q23. It carries either an arginine (FcγRIIIa-R131) or histidine (FcγRIIIa-H131) at the amino acid position 131 due to a G to A point mutation in exon 4 of FcγRIIIa. FcγRIIIa has an important role in the pathogenesis of autoimmune diseases. It bears a phenylalanine (FcγRIIIa-158F) or valine (FcγRIIIa-158V) at amino acid position 158 due to G to T point mutation at FcγRIIIa-158. FcγRIIIb, most commonly found in neutrophils, increases the capability of phagocytosis especially against gram-negative microorganisms. It bears the neutrophil antigen (NA) polymorphism caused by four amino acid substitutions, with wild type named NA1, and a polymorphic variant named NA2 (9,10).

Our aim in this case-control study is to determine the role of FcγR polymorphisms in urinary tract infections, to investigate the genotypic diversity of FcR, and to demonstrate phenotype-genotype relationship in UTI.

MATERIALS

One-hundred thirty-one patients presented with a UTI but did not have a vesicoureteral reflux or any other congenital anomaly (107 females and 24 males with the mean age of 7.21±4.19 years and age disturbance range was 1 month -17 years) and 151 healthy Turkish subjects (73 females and 78 males with a mean age of 9±4.2 years), without any laboratory (complete blood cell count and acute phase reactants), abnormal

physical examination finding, or past history of UTI or urinary tract abnormality, based upon renal ultrasonography, participated in our study.

Infections were defined by a positive urine culture. The indirect laboratory criteria for localization of UTI were fever, erythrocyte sedimentation rate, C-reactive protein, leukocytosis and urine osmolality. A patient with three or more of these criteria was clinically diagnosed to have an upper UTI. Upper/lower UTI ratio was 70/61. Reinfection was defined as the recurrence of infection with a different pathogen, while relapse was defined as the recurrence of the infection with the same pathogen.

Patients with recurrent UTI and pyelonephritis were investigated with ^{99m}Tc-DMSA for renal damage, the renal Scar (+)/ (-) ratio was 30/101. Renal scarring was classified with the Goldraich scarring grade from Type 1 to Type 4 (11).

Type 1 less than 2 renal scars

Type 2 more than 2 renal scars with normal parenchymal area in between

Type 3 generalized parenchymal damage

Type 4 atrophic kidneys (with <10% function)

The University Ethical Research Committee approved the study. Parents of subjects and controls provided written informed consent prior to the study.

Both patients and controls were investigated for FcγR polymorphisms. Polymorphisms were analyzed by allele-specific PCR and a direct DNA sequencing based method from genomic DNA.

Methods

DNA purification

Genomic DNA from patients and healthy controls was extracted from peripheral blood leukocytes with QIAamp DNA Blood Mini Kits (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.

FcγRIIIa genotyping

FcγRIIIa genotyping (figure1) was performed by using the method defined by Flesch BK et al (12). We used a 25-μL PCR mixture containing 2.5 μL of genomic DNA, 2.5 μL of 10× PCR buffer (Applied Bio systems, Foster City, CA, USA), 2 mM MgCl₂, 200 μmol/L of each dNTP (Promega, Madison, USA), and 0.5 U Ampli Tag DNA Polymerase (Applied Bio systems).

In addition, 0.5 μmol/L of H131-specific sense primer (5'- ATCC-CAGAAATTCTCCCA-3') from the second extracellular domain or 0.5 μmol/L R 131-specific sense primer (5'-ATCCCAGAAATTCTCCCG-3') was used. Qiagen Operon Co synthesized all primer oligonucleotides, 0.5 μmol/L common anti-sense primer from an area downstream of the intron (5'-CAATTTTGCTGCTATGGGC-3'). The resulting fragment was 253 bp in length. As an internal PCR control, we

used 0.125 $\mu\text{mol/l}$ human growth hormone (HGH)-1 forward primer (5'-CAGTGCCTTCCCAACCATTCCTTA-3') and 0.125 $\mu\text{mol/l}$ HGH-II reverse primer (5'-ATCCACTCACGGATTTCTGTTGTGTTTC-3'), which resulted in a 439-bp fragment.




Figure 1: Fc γ RIIa genotyping

A thermal cycler (Gene Amp 9700, Applied Bio systems) was used to perform a hot-start PCR as follows; 5 min at 95 °C, 10 cycles of 1 min at 95 °C, 2 min at 57 °C, and 1 min at 72 °C; thereafter, to enhance the sensitivity, we used 22 cycles of 1 min at 95 °C, 2 min at 54 °C, and 1 min at 72 °C and a final extension step for 5 min at 72 °C. The PCR amplification products were separated on a 2% agarose gel and visualized by ethidium bromide staining. To validate accuracy and reproducibility of the results obtained using the above-described techniques, we randomly ran 20% of samples from both groups (study and control groups) for Fc γ RIIa genotypes by using a direct DNA sequencing technique with ABI PRISM 310 Genetic Analyzer System (Applied Bio systems).

Polymerase chain reaction for Fc γ RIIIa (PCR):

In the case of Fc γ RIIIa genotyping (figure 2), primer (KIM-G (V): 5'-TCT CTG AAG ACA CAT TTC TAC TCC CTA C-3' and KIM-1 (F): 5'-TCT CAT AAG ACA CAT TTC TAC TCC CTA A-3') primer A013 (5'-ATA TTT ACA GAA TGG CAC AGG-3')




Figure 2: Fc γ RIIIa receptor genotyping

Control primers Ctrl-1 and Ctrl-2, as explained in Fc γ RIIIa, DNA's fragments of 270-bp multiplied. This process was made in a 25 μl reaction solution using 175 ng of genomic DNA. The reaction solution containing: 2.5 μl PCR Gold Buffer, 62.5 nmol MgCl₂, 1.25 nmol, from each of the four dNTP, 11.9 pmol KIM-G (V), 66.4 pmol KIM-G (F), 15.4 pmol A013, 1.1 pmol from each of the two control primers and 0.5 U Ampli Tag Gold (Applied Bio systems).

PCR was denaturated at 94° in 10 minutes. 32 cycles of 30 seconds at 95°C, thereafter 32 cycles for 20 seconds at 57°C and for 25 seconds at 72°C and a final extension step for 7 minutes at 72°C.

Fc γ RIIIB genotyping

In the case of Fc γ RIIIB-NA1/NA2 genotyping (figure 3), PCR was modified from Bux et al (13). The NA1-specific primer (5VCAGTGGTTTCACAATGTG AA-3V) gave a 141-bp fragment, and the NA2-specific primer (5V-CAATGGTACAGCGTGCTT- 3V) amplified a 219-bp fragment. The reverse primer (5V-ATGGACTTCTACCTGCAC-3V) did not discriminate between the two allotypes. Because there was a substantial difference in length between the NA1-specific and NA2-specific reaction products, both alleles could be detected in the same reaction. The 25- μl reaction mixture used contained 100 ng of genomic DNA, 3.7 μl of 10x PCR buffer (Applied Bio systems), 25 nM MgCl₂, 1 nmol/l of each dNTP (Promega), 4 pmol of each of the control primers, 0.012 nmol of the NA1 and NA2 primers, 0.025 nmol of the reverse primer, and 0.5 U AmpliTaq DNA Polymerase (Applied Bio systems). After denaturation for 3 min at 95°C, 30 PCR cycles consisting of 95°C for 1 min, 57°C for 2 min, and 72°C for 1 min were run. After a final extension step of 1 min at 72°C, samples were resolved in 2% agarose gels stained with ethidium bromide.




Figure 3: Fc γ RIIIB receptor genotyping

Statistics

Statistical analysis of the data was performed with SPSS package v.11.0 program. The allele distribution Fc γ R polymorphism was tested with the Hardy Weinberg equilibrium equation in patient and control

groups. The chi-square test and Fisher's exact test were used for comparison of the groups for genotypic distribution and allelic frequencies. The data was expressed as mean ± standard deviation (SD) and *p* value less than 0.05 and an odds ratio with 95% of confidence not including 1 was considered as statistically significant.

RESULTS

Genotypic distributions of the case-control study did not deviate significantly from the Hardy-Weinberg equilibrium expectations in each group (*P*>0.05). The most common pathogen was E. coli (n=90) and Gram (-) infections were seen in 108 patients. With respect to the localization of UTI, the upper and lower UTI ratio was similar to each other. Complicated UTI, renal scarring and relapse were found to be more frequent in upper UTI whereas reinfection was more common in the lower UTI group (Table 1).

	Upper UTI n=70 (%)	Lower UTI (n=61) (%)	Total UTI n= 131 (%)
Renal scarring	21 (30)	9 (14.7)	30 (%23)
Relapsing	39 (55.7)	11 (18)	50 (%38)
Reinfection	23 (32.8)	33 (54)	56 (42.7)
Complicated	41 (58.5)	16 (26.2)	57 (42.8)

Table 1: UTI clinical forms and localization in study group

FcγRIIIa Genotype Distribution and Allele Frequency

In study group, FcγRIIIa R/R genotype and FcγRIIIa R allele were found significantly higher than in the control group (Table 2).

Group	H131 H	H131 R	R131 R	H	R
Control (n=151)	78	59	14	215(%72)	87 (%28)
UTI(n=131)	51	59	21	161(%61)	101(%39)
p	ns	ns	0,01	ns	0.01

Table 2: FcγRIIIa Genotype Distributions and Allele Frequency
The chi-square test and Fisher's exact tests are used for comparison of the groups for genotypic distribution and allelic frequencies

FcγRIIIa Genotype Distribution and Allele Frequency

FcγRIIIa genotype distribution and allele frequency is not significantly different between the UTI and control group, which is due to the fact that the basic function of

this receptor is related to autoimmune diseases (Table 3).

Group	F158F	F158V	V158V	F	V
Control(n=151)	53	67	31	173(%57)	129(%43)
UTI(n=131)	33	84	14	150(%57)	112(%43)
P	ns	Ns	ns	Ns	ns

Table 3: FcγRIIIa Genotype Distributions and Allele Frequency
The chi-square test and Fisher's exact tests are used for comparison of the groups for genotypic distribution and allelic frequencies

FcγRIIIb Genotype Distribution and Allele Frequency

FcγRIIIb-NA2/NA2 genotype and NA2 allele were found to be statistically higher when compared to the control group (Table 4).

Group	NA1/NA1	NA2/NA2	NA1/NA2	NA1	NA2
Control (n=251)	37	57	57	131 (%43)	171 (57)
UTI (n=108)	14	75	19	47 (%21)	169 (79)
P	ns	P<0.001	ns	ns	P<0.001

Table 4: FcγRIIIb genotype distributions and allele frequency

Relations of FcγRIIIa-131-R Allele Polymorphisms with Phenotypic Features

FcγRIIIa-131-R allele was found to be related with lower urinary tract infections (*OR* =1.12, 95 % *CI* 0.86-1.46, *p*=0.015) and gram-negative bacterial infection risk (*OR*= 1.20, 95 % *CI* 0.7-1.4, *p*=0.012) (Table 5).

Allele (n)	Upper UTI	Lower UTI	E.Coli	Gram (-)
R (+)	41	40	61	67
R (-)	29	21	31	41

Table 5: Relations of FcγRIIIa-131-R Allele Polymorphisms with Phenotypic Features

Relations of FcγRIIIb-N Allele Polymorphisms with Phenotypic Features

The FcγRIIIb-NA2 allele was found to related with upper UTI (*OR* =1.11, 95 % *CI* 0.4-2, *p*=0.001), gram-negative bacterial infection (*OR*= 1.2, 95% *CI* 0.85-1.4, *p*=0.001)and renal scar development risk(*OR*=1.95% *CI* 0.76-1.37,*p*=0.001) (Table 6).

Allele(n)	Upper UTI	Lower UTI	Renal Scar	E.Coli	Gr (-)
NA2+	49	44	22	64	80
NA2-	8	7	3	11	11

Table 6: Relations of FcγRIIIb-N Allele Polymorphisms with Phenotypic Features

DISCUSSION

Urinary tract infection is a common problem, which differs in clinical severity from asymptomatic bacteriuria to pyelonephritis. It may be recurrent due to anatomic anomalies, environmental factors and immune-system defects. Determining the risk factors

will prevent long-term sequel of UTI, such as hypertension, renal scarring and renal failure. Genetic factors which may lead to a predisposed UTI susceptibility is still unknown.

In recent years, genetic studies have suggested that receptors for the Fc fragments of immunoglobulin G (IgG) (FcγRs) may be implicated in the susceptibility or the progression of some autoimmune and infectious diseases. Receptors for IgG play an important role in immune complex clearance and immune response (14-16).

There is limited study in the literature regarding the FcγRIIIa genotype and its relationship to infectious disease. Researchers examined FcγRIIIa-158FF, FcγRIIIa-158VV, FcγRIIIa-158VF polymorphisms and FcγRIIa and FcγRIIIb polymorphisms coexistence in 462 adults from Thailand with a Plasmodium falciparum malaria infection. Nevertheless, they did not find any relationship between the severity of malaria and polymorphisms (17).

In this study, we found no significant relationship with FcγRIIIa polymorphism in patients with a UTI and the control group ($p=0.63$), we suspect this is because the main function of the receptor is related to autoimmune disease processes. FcγRIIIa has a role in clearance of circulating immune complexes, but has no correlation with UTI tendency.

A predisposition to certain bacterial infections has been observed with a histidine to arginine substitution at the amino acid position 131, affecting FcγRIIa and receptor binding of IgG₂ (18,19). The leucocytes carrying the FcγRIIa-131RR genotype have lower phagocytic ability for immunoglobulin G₂ opsonized particles than the leucocytes carrying the FcγRIIa-131HH genotype (20,21). In American patients with bacterial pneumonias, we found the FcγRIIa-131RR genotype to have an increased frequency (22), and increased host sensitivity due to FcγRIIa-IgG₂ association was not observed. IgG₂ is the most important immunoglobulin subgroup in patients, as it provides protection against capsulated pathogens, such as Neisseria meningitis, Haemophilus influenza and Streptococcus pneumonia. Patients carrying the FcγRIIa-131HH genotype showed increased phagocytic activity against IgG₂ opsonized bacteria when compared to FcγRIIa-131RR homozygote genotype carrying patients. In one study investigating the severity of Neisseria meningitis infection with the FcγRIIa gene polymorphism, it was reported that hosts carrying only FcγRIIa-131RR polymorphism had a more severe disease and severe complications (23). Fang Fang Yuan et al. reported that Australian patients the FcγRIIa-131RR polymorphism had more occurrences of Streptococcus pneumonia sepsis, as

compared to the healthy control group; in addition, the FcγRIIa-131HH polymorphism was very rare as compared to the FcγRIIa-131RR genotype in these patients (24).

In our study, we found that the FcγRIIa-131RR genotype and FcγRIIa-131R allele frequency was significantly higher in the patient group as compared to the control group ($p<0.05$). Patients with the FcγRIIa-131R allele have a significantly higher risk of a lower UTI and gram-negative bacterial infections than others. Although the occurrence of a complicated UTI, upper UTI, renal scarring and recurrence and reinfection rates were not different than patients without the FcγRIIa-131R allele.

FcγRII regulates the stimulation of neutrophils degranulation and phagocytic functions. A neutrophil functional deficiency due to an FcγRIIa polymorphism may be one factor causing patients to have a predisposition to UTIs.

FcγRIIIb is the most common Fcγ receptor found in neutrophils and shows neutrophil antigen (NA) polymorphism. These polymorphic glycoproteins called -NA1 and -NA2 (100). FcγRIIIb-NA1/NA1 induces IgG₁ and IgG₃ opsonized particles to undergo phagocytosis. Neutrophils with the FcγRIIIb-NA1/NA1 genotype have a stronger phagocytic ability than neutrophils with the FcγRIIIb-NA2/NA2 alleles (25).

In our study, the FcγRIIIb-NA2/NA2 polymorphism and -NA2 allele were found to be statistically significantly higher in the patient group than in the control group. In patients with the FcγRIIIb-NA2 allele, they had a significantly more upper UTIs and lower UTIs, infection recurrence, renal scar development risk, more UTIs caused by a gram negative pathogen, and a higher potential to develop a complicated UTI than without NA2.

FcγRIIIb, which is the most common receptor found on neutrophils, with an ability to enhance the phagocytic capability against gram negative bacteria, has been shown to have a higher polymorphism ratio in children with UTIs. We thought that 82.7% of microorganisms, which were most commonly identified from urine cultures, have been found gram (-) bacteria therefore this polymorphism could be an important risk factor in development of UTI.

The studies investigating FcγRIIa, FcγRIIIa and FcγRIIIb genotypes conducted in different healthy ethnic groups showed that genotypic diversity exists between different ethnic groups. The FcγRIIa-131RR genotype was found to be lowest in in Japan with a ratio of 3.8%. This was similar for our study, with a ratio of 9.2% in Turkish children for FcγRIIa-131RR.

The higher ratios, such as 50-60% for FcγRIIa-131HH genotype, can be explained by existence of an innate

resistance against capsulated bacteria. Finding of lower FcγRIIa-131RR genotype ratio can decrease tendency to infections in these ethnic groups. FcγRIIa and FcγRIIb polymorphisms have an important role in the development of a genetic tendency toward bacterial infections. At the same time, the severity of a bacterial infection and the frequency of a bacterial infection, are also directly affected.

UTI has a very important place among pediatric bacterial infections; to the best of our knowledge there is no other study conducted for investigation of a relationship between pediatric UTIs and the FcγR receptor in the literature.

FcγRIIa and FcγRIIb polymorphisms were thought to be risk factors for patients with a definite UTI. We have found the more common FcγRIIb polymorphism in our patients; therefore it likely results in a deficiency of the neutrophil phagocytic capacity for gram-negative pathogens. More gram-negative bacterial growth, as seen more often in urine cultures, may be related with this polymorphism. People with the FcγRIIb-NA2/NA2 polymorphism have less effective gram-negative bacterial phagocytosis capacity. In particular, people carrying the FcγRIIb-NA2/NA2 polymorphism or FcγRIIa-131RR and FcγRIIb-NA2/NA2 genotype coexistence, have more severe meningococcal infections and complications (20,26).

As a result, investigation of FcγR polymorphisms is useful when there is a diagnosis of an upper UTI or complicated UTI in patients without factors predisposing them to a UTI, such as an underlying congenital urinary tract abnormality, VUR etc. We must be more careful when clinically following and providing prophylaxis for patients carrying the FcγRIIa-131RR or FcγRIIb-NA2/NA2 genotypes, as the ratio of serious complications, such as renal scar development, a prime cause of hypertension and renal failure, could be decreased.

In conclusion FcγRIIa and FcγRIIb polymorphisms are thought to be risk factors for a predisposition to a UTI. The FcγRIIa-131-R allele was found to related with lower urinary tract infections and gram-negative bacterial infection risk. The FcγRIIb-NA2 allele was also found to be related with an increased occurrence of upper UTIs, gram-negative bacterial infection and renal scar development risk.

REFERENCES

1. Jodal U, Hansson S. Urinary tract infection. In: Holiday MA, Barrat TM, Pediatric Nephrology. Third edition. Baltimore: Williams and Wilkins; 1994: 950-963, Hofstetter A. Rationalliediagnostik von harnweginfektionen. Fortschr Med 1991; 33:677-679
2. Svanborg Eden C, Hausson S, Jodal U, Lidin-Janson G, Lincoln K, Linder H, Lomberg H, De Man P, Marild S, Martinell J (1988). Host-parasite interaction in the urinary tract. J Infect Dis 157(3):421-426

3. Van de Winkel JG, Ernst LK, Anderson CL, Chiu IM (1991). Gene organization of the human high affinity receptor for IgG, Fc gamma RI (CD64). Characterization and evidence for a second gene. J BiolChem 266(20):13449-55
4. De Wit TP, Suijkerbuijk RF, Capel PJ, Van Kessel AG, Van De Winkel JG (1993). Assignment of three human high-affinity Fc gamma receptor I genes to chromosome 1, band q21.1. Immunogenetics 38(1):57-9
5. Van De Winkel JG, Capel PJ (1993). Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14(5):215-21
6. Ravetch JV, Kinet JP (1991). Fc receptors. Annu Rev Immunol 9:457-92
7. Maenaka K, Van Der Merwe PA, Stuart DI, Jones EY, Sondermann P (2001). The human low affinity Fc gamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J BiolChem 276(48):44898-904
8. Salmon JE, Kimberly RP, Gibofsky A, Fotino M (1984). Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. J Immunol 133(5):2525-31
9. Van Sorge NM, Van Der Pol WL, Van De Winkel JG (2003). FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61(3):189-202
10. Van der Pol W, van de Winkel JG (1998). IgG receptor polymorphisms: risk factors for disease. Immunogenetics 48(3):222-32
11. Goldraich NP, Ramos OL, Goldraich IH (1989). Urography versus DMSA scans in children with vesicoureteric reflux. PediatrNephrol 3(1):1-5
12. Flesch BK, Bauer F, Neppert J (1998). Rapid typing of the human Fc gamma receptor IIA polymorphism by polymerase chain reaction amplification with allele-specific primers. Transfusion 38: 174- 176
13. Bux J, Stein EL, Santoso S, Eckhardt Mueller C (1995). NA gene frequencies in the German population, determined by polymerase chain reaction with sequence specific primers. Transfusion 35: 54- 57
14. Van Sorge NM, van der Pol WL, van de Winkel JG (2003). FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61(3):189-202
15. Dijkstra HM, Scheepers RH, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW (1999). Fc gamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 42(9):1823-7
16. Tse WY, Abadeh S, Jefferis R, Savage CO, Adu D (2000). Neutrophil Fc gamma RIIBb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. ClinExpImmunol 119(3):574-7
17. Omi K, Ohashi J, Patarapotikul J, Hananantachai H, Naka I, Looareesuwan S, Tokunaga K (2002). Absence of association between the Fc gamma receptor IIIA-176F/V polymorphism and the severity of malaria in Thai. Jpn J Infect Dis 55(5):167-9
18. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP (1996). Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97(5):1348-54
19. Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, de Haas M, Capel PJ, Zegers BJ (1994). Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 170(4):854-61
20. Salmon JE, Edberg JC, Brogle NL, Kimberly RP (1992). Allelic polymorphisms of human Fc gamma receptor IIA and Fc

- gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. *J Clin Invest* 89(4):1274-81
21. Bredius RG, de Vries CE, Troelstra A, van Alphen L, Weening RS, van de Winkel JG, Out TA (1993). Phagocytosis of *Staphylococcus aureus* and *Haemophilus influenzae* type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. *J Immunol* 1;151(3):1463-72
 22. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM (2000). Association between Fc gamma RIIa-R131 allotype and bacteremic pneumococcal pneumonia. *Clin Infect Dis* 30(1):25-8
 23. Domingo P, Muniz-Diaz E, Baraldes MA, Arilla M, Barquet N, Pericas R, Juarez C, Madoz P, Vazquez G (2004). Relevance of genetically determined host factors to the prognosis of meningococcal disease. *Eur J Clin Microbiol Infect Dis* 23(8):634-7
 24. Fang Fang Yuan, Melanie Wong, Natalia Pererva, Joanna Keating (2003). Fc gamma RIIa polymorphisms in *Streptococcus pneumoniae* infection. *Immunology and Cell Biology* 81, 192-195.
 25. Salmon JE, Edberg JC, Kimberly RP (1990). Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. *J Clin Invest* 85(4):1287-95
 26. Van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG (2001) Relevance of Fc gamma receptor and interleukin-10 polymorphisms for meningococcal disease. *J Infect Dis* 184(12):1548-55